IL1B and COVID-19: The lack of efficacious licensed therapies to treat severe COVID‐19 patients by targeting SARS‐CoV‐2 has led clinical colleagues to consider and trial drugs based on modulating the immune response, such as anti‐inflammatories to reduce the inflammation, and the use of biologics targeting some of the cytokines reported to be up‐regulated in patients such as IL1β, IL‐6 and TNFα (Tay et al, 2020).